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Abstract
Mutations in genes encoding presenilin-1 (PS1) and presenilin-2 (PS2) have been linked to familial forms of Alzheimer’s
disease (AD). Cells expressing mutant presenilins produce elevated levels of AL42, the major amyloid peptide found in AD
plaques. The mechanism whereby this occurs remains unknown, but the localization of presenilins to endoplasmic reticulum
(ER) and Golgi compartments has suggested that they may function in intracellular trafficking pathways involved in
processing L-amyloid precursor proteins (APP). To test this possibility, we coexpressed PS1(wt), PS1(M146L), or
PS1(L286V) in HEK293 cells together with the LDL receptor, a classic glycoprotein marker that undergoes post-
translational O-glycosylation in the Golgi compartment. Pulse-chase analysis of the receptor indicated that mutant
presenilins had no effect on ERCGolgi transport. Similar results were obtained when the studies were carried out with cells
expressing the Swedish variant of APP (SWAPP751) instead of the LDL receptor. Moreover, secretion of the soluble
exodomain polypeptide fragments of SWAPP751 that arise from K-secretase and L-secretase cleavage was not markedly
affected by the PS1 mutants. Despite the lack of discernible effect of the PS1 mutants on trafficking of proteins through the
Golgi apparatus, they caused a substantial increase in the proportion of AL42 relative to total AL in the culture medium. The
results suggest that mutant forms of PS1 cause elevated production of AL42 by a mechanism that is independent of a major
disruption of exocytic trafficking of APP. z 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Amyloid L-peptide (AL) is a major component of
cerebral amyloid plaques in Alzheimer’s disease
(AD). AL is formed in neurons and other cell types
through proteolytic processing of a membrane-an-
chored glycoprotein precursor; L-amyloid precursor
protein (APP) [1^3]. Processing of APP can occur via
at least two alternative routes: the bulk of APP en-
ters a non-amyloidogenic pathway in which the pre-
cursor is ¢rst cleaved within the AL domain by a
protease termed K-secretase, leaving a C-terminal
fragment that is subsequently cleaved by Q-secretase.
In the alternative amyloidogenic pathway, APP is
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initially cleaved proximal to the AL sequence by an
activity termed L-secretase, leaving a C-terminal frag-
ment that can give rise to AL when it is ¢nally
cleaved by Q-secretase. It is now well established
that cells can produce alternate forms of AL that
di¡er in overall chain length (e.g. AL40 and AL42),
with the longer forms being the most prone to form
insoluble amyloid deposits [4^6]. Moreover, recent
evidence suggests that the di¡erent forms of AL
may be generated through the action of distinct Q-
secretase activities [7,8].
Some early-onset familial forms of AD are known
to be associated with mutations in APP which result
in an increased proportion of the protein being proc-
essed via the amyloidogenic route [9^12]. More re-
cently, mutations in a new class of genes encoding
proteins termed presenilin-1 (PS1) [13] and preseni-
lin-2 (PS2) [14] have also been linked to familial AD.
In particular, mutations in PS1 appear to account for
the majority of cases of early-onset familial AD
[15,16]. PS1 and PS2 are polypeptides of 467 and
448 amino acids, respectively, that are predicted to
have serpentine structures with multiple hydrophobic
membrane-spanning segments [13,17,18]. Although
the biological functions of the presenilins are not
yet known, recent evidence suggests that mutations
in these proteins may somehow alter the processing
of APP in manner that favors increased production
of AL42 [19^22].
Presenilins show signi¢cant similarity to two pro-
teins in Caenorhabditis elegans ; i.e. Sel-12 [23] and
Spe-4 [24]. Spe-4 appears to be involved in the for-
mation of a specialized Golgi-derived structure
termed the ¢brous body membrane organelle during
spermatogenesis. Sel-12 facilitates signaling though
the lin-12/Notch family of receptors, possibly
through e¡ects on localization or recycling of the
receptors. Interestingly, expression of PS1 can com-
pensate for defects in sel-12 in C. elegans, suggesting
functional homology between Sel-12 and the preseni-
lins [25]. The foregoing observations, coupled with
immunolocalization studies indicating that PS1 is
distributed primarily in the endoplasmic reticulum
(ER) and Golgi apparatus [26^30], have raised the
intriguing possibility that presenilins could be com-
ponents of the intracellular machinery for vesicular
transport and protein tra⁄cking. If true, this could
have important implications for the mechanism
whereby presenilin mutants increase production of
AL42. For instance, recent reports have provided evi-
dence that, unlike AL40, AL42 may be generated pre-
dominantly within the ER [31,32]. Thus, one can
envision a mechanism wherein impairment of normal
ERCGolgi tra⁄cking of APP by mutant presenilins
might increase the biogenesis of AL42 by allowing
nascent APP to be retained in an early subcellular
compartment containing the AL42-forming Q-secre-
tase activity.
In the present study, we have tested the hypothesis
that mutant forms of PS1 implicated in familial AD
produce elevated levels of AL42 through a disruption
of ERCGolgi protein tra⁄cking. This was done by
assessing the e¡ects of wild-type and mutant forms
of PS1 on the post-translational processing of a mod-
el glycoprotein, the human low density lipoprotein
(LDL) receptor, as well as the Swedish variant of
APP in transfected human 293 cells.
2. Materials and methods
2.1. Expression vectors
The pohCk751sw mammalian expression vector
has been described previously [33]. It encodes the
Swedish variant of APP751 which contains a dual
amino acid change (K651CN; M652CL) that in-
creases the susceptibility of the protein to amyloido-
genic processing [10^12]. The plasmid, pLDLR17
which contains the full-length sequence encoding
the human LDL receptor inserted into pCMV4
[34], was provided by David Russell, University of
Texas Southwestern Medical Center. The cDNA en-
coding human PS1 was obtained by polymerase
chain reaction (PCR) ampli¢cation as follows: Total
cDNA was synthesized from human brain poly(A)
RNA (Clontech, Palo Alto, CA) using SuperScript II
reverse transcriptase (Gibco, Gaithersburg, MD) and
oligo-dT primer. The brain cDNA was then used as
template in a PCR reaction containing a 20:1 ratio
of AmpliTaq DNA polymerase and ULTma DNA
polymerase (Perkin^Elmer, Foster City, CA) and
primers £anking the PS1 sequence (5P-CAGGGTC-
GCGATGACAGAGTTACCTGCACCGTTGTCC-
TAC and 5P-GCCTGACTAGTCTAGATATAAA-
ATTGATG-GAATGCTAATTG). The ¢rst-round
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product obtained after 30 cycles (0.5 min at 94‡C, 1
min at 57‡C and 5 min at 72‡C) was used as a tem-
plate in a second-round PCR reaction under the
same conditions to obtain su⁄cient material for
cloning. The ¢nal PS1 product was cloned into pNo-
TA/T7 (5 PrimeC3 Prime, Boulder, CO) and the
DNA sequence was determined. The individual mu-
tations L286CV and M146CL were created in the
recombinant plasmid, pNoTA/T7(PS1), using the
Transformer site-directed mutagenesis kit as directed
by the manufacturer (Clontech, Palo Alto, CA). The
wild-type and mutant PS1 genes were then subcloned
into the mammalian expression vector, pohCk751
[33], using the NruI and SpeI restriction sites.
2.2. Transfection of cultured cells
Transformed human embryonal kidney cells (line
293), obtained from American Type Culture Collec-
tion, were maintained at 37‡C in a 5% CO2 atmos-
phere in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) containing 10% (v/v) fetal bovine serum
(FBS). Cells were plated in 60-mm dishes at
7.5U105 cells/dish on the day before transfection.
In studies aimed at assessing the e¡ects of PS1 mu-
tants on processing of the LDL receptor, paral-
lel cultures were co-transfected with pLDLR17
in combination with either pohCkPS1(wt),
pohCkPS1(M146L), or pohCkPS1(L286V), using
Superfect transfection reagent according to the pro-
tocol recommended by the manufacturer (Qiagen). In
separate studies designed to evaluate the e¡ects of
PS1 mutants on APP processing, the same approach
was used, except that the PS1 constructs were co-
transfected with pohCk751sw instead of pLDLR17.
2.3. Metabolic labeling and immunoprecipitation of
LDL receptor or APP
Twenty-four hours after transfection, cultures were
pulse-labeled for 30 min at 37‡C with 1 ml methio-
nine-free DMEM containing 100 WCi of
[35S]methionine/cysteine (Trans-label, 1100^1200 Ci/
mmol, ICN). The cells were then washed twice with
PBS and subjected to a 2 h chase in DMEM con-
taining 10% FBS, 2 mM methionine, and 2 mM cys-
teine. Cells were harvested from parallel cultures at
the end of the pulse and chase periods and cell ex-
tracts were prepared by disrupting the cells in phos-
phate-bu¡ered saline solution (PBS) containing 1%
(v/v) Triton X-100. The lysates were cleared by cen-
trifugation at 10 000Ug for 10 min at 4‡C, and one-
tenth of the supernatant solution was removed for
assessment of protein expression levels by immuno-
blot analysis. The remainder of the sample was used
for immunoprecipitation of radiolabeled LDL recep-
tor [35] or APP [33] as described previously. Precipi-
tated proteins were subjected to SDS-PAGE and
autoradiography and the radioactivity incorporated
into the processed versus unprocessed forms of LDL
receptor or APP was quanti¢ed using a Molecular
Dynamics phosphorimager and ImageQuant soft-
ware.
2.4. Immunoblot analysis
Aliquots of cell lysates or conditioned culture me-
dium were mixed with 2USDS sample bu¡er so that
the ¢nal composition was 8 M urea, 2% w/v SDS, 5%
v/v 2-mercaptoethanol, 10% v/v glycerol, 62.5 mM
Tris-HCl, pH 6.8. Proteins were resolved by SDS-
PAGE, using 10% polyacrylamide gels for analysis
of PS1 and 6.5% polyacrylamide gels for analysis
of the LDL receptor or APP. Proteins were trans-
ferred to Immobilon-P (Millipore) and the mem-
branes were preincubated for 1 h in blotting solution
(PBS containing 5% w/v powdered milk and 0.1% v/v
Tween 20). PS1 was detected with a polyclonal anti-
body (199) raised against a KLH-coupled peptide
corresponding to amino acids 333^347 in the large
cytoplasmic loop of PS1. Intracellular APP751 and
total secreted forms of APP (s-APPtotal) were de-
tected with monoclonal antibody 8E5 [36]. The se-
creted exodomain fragment released from SWAPP751
as a result of L-secretase cleavage (s-APPL) was de-
tected with a polyclonal antibody, SW192 [37]. All
primary antibodies were used at a ¢nal concentration
of 0.1 Wg/ml, and immunoblotting procedures were
carried out as described previously [33,38]. For
chemiluminescent detection with the ECL kit (Amer-
sham), horseradish peroxidase-conjugated goat anti-
rabbit IgG or goat anti-mouse IgG were obtained
from Bio-Rad and used at 1:3000 v/v dilution. For
quantitative immunoblot analysis of intracellular and
secreted forms of APP, 125I-labeled goat anti-mouse
IgG or goat anti-rabbit IgG were obtained from Du-
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Pont/NEN and used at a ¢nal concentration of 0.45
WCi/ml. Bound [125I]IgG was detected by autoradiog-
raphy and quanti¢ed by phosphorimager analysis.
2.5. ELISA for AL
Conditioned medium (3 ml total) was collected
from each culture between 24^48 h after transfection.
Aliquots of medium were preadsorbed with heparin-
agarose and the concentrations of total AL or AL42
were determined by sandwich-type ELISA, as de-
scribed previously [38].
3. Results
3.1. E¡ect of PS1 mutants on Golgi-dependent
processing of the human LDL receptor
The nascent human LDL receptor is modi¢ed by
high-mannose N-linked carbohydrate chains in the
ER and exhibits an apparent molecular mass of
120 kDa when subjected to SDS gel electrophoresis.
Upon its translocation to the Golgi apparatus, the
protein is converted to a mature form which migrates
at approximately 160 kDa [39]. The shift in electro-
phoretic mobility re£ects the addition of O-linked
oligosaccharide chains, and to a lesser extent, the
trimming and sialylation of the N-linked carbohy-
drates [40]. Thus, the change in mobility of the
LDL receptor provides a convenient means to mon-
itor glycoprotein tra⁄cking from the ER to the Gol-
gi compartment. For example, in a previous study,
we showed that disruption of ERCGolgi vesicular
transport by expression of a dominant-negative
Rab1B GTPase mutant in 293 cells prevents the con-
version of nascent LDL receptor to the mature high-
molecular mass form [35].
To examine the possibility that mutant forms of
PS1 might cause elevated levels of AL42 through a
general perturbation of ERCGolgi protein trans-
port, we initially tested the e¡ects of wild-type and
mutant forms of PS1 on the maturation of the LDL
receptor. HEK293 cells were co-transfected with ex-
pression vectors encoding the human LDL receptor,
either alone or in combination with vectors encoding
PS1(wt), PS1(M146L), or PS1(L286V). Twenty four
hours after transfection, the cells were pulse-labeled
with [35S]methionine and maturation of the LDL re-
ceptor was assessed by electrophoretic analysis of the
immunoprecipitated protein. As shown in Fig. 1A,
no radiolabeled LDL receptor was detected in 293
cells that received the PS1(wt) plasmid alone, signi-
fying that background expression of endogenous
LDL receptor was extremely low. Cells that received
the LDL receptor plasmid alone showed e⁄cient
ERCGolgi dependent processing of the expressed
protein, with the 120 kDa precursor form of the
receptor predominating immediately after the pulse-
labeling period and the 160 kDa mature form of the
protein predominating at the end of the 2-h chase.
Fig. 1. E¡ects of wild-type or mutant PS1 on post-translational
maturation of the human LDL receptor expressed in 293 cells.
(A) Parallel cultures of human HEK293 cells were co-trans-
fected with expression vectors encoding the LDL receptor com-
bined with empty vector (none) or vector encoding either
PS1(wt), PS1(M146L), or PS1(L286V) as indicated. Twenty
four hours after transfection the medium was changed and cells
were pulse-labeled with [35S]methionine for 30 min, then sub-
jected to a 2 h chase as described in Section 2. Cells were har-
vested immediately after pulse-labeling (0 h) or after the chase
(2 h) as indicated and the immunoprecipitated LDL receptor
was subjected to SDS-PAGE and £uorography. The immature
(i) and mature (m) forms of the receptor are indicated by the
arrows at the left of the ¢gure. (B) Immunoblot analyses were
performed on aliquots of the cell lysates from the cultures har-
vested at the end of the chase period to con¢rm expression of
PS1 constructs, using a polyclonal antibody against the large
cytoplasmic loop of PS1 as described in Section 2. Speci¢c
bands corresponding to overexpressed PS1 are indicated on the
left of the ¢gure. Results similar to those described in this ¢g-
ure were obtained in two additional experiments.
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(Fig. 1A). In parallel cultures where the LDL recep-
tor was coexpressed with PS1(wt), PS1(M146L), or
PS1(L286V), the results were essentially the same as
in the cultures where the receptor was expressed
without PS1; i.e. nearly all of the nascent receptor
was converted to the mature 160 kDa form by the
end of the chase (Fig. 1A). This contrasts markedly
with the readily detected perturbation of LDL recep-
tor maturation observed in our previous studies
where ERCGolgi transport was blocked by expres-
sion of a dominant-negative mutant form of the
Rab1B GTPase in 293 cells [35].
To verify that PS1 proteins were indeed expressed
in the transfected cells, aliquots of the cell lysates
used for immunoprecipitation of the LDL receptor
were subjected to immunoblot analysis using a poly-
clonal antibody against PS1 (Fig. 1B). Consistent
with previous studies [26,41^43], full-length PS1,
which migrates at approximately 42 kDa, was readily
detected in cells that were transfected with constructs
encoding PS1(wt), PS1(M146L), or PS1(L286V), but
not in cells that received the LDL receptor plasmid
alone. All of the cultures expressing PS1 also con-
tained substantial amounts of immunoreactive pro-
tein in the high molecular weight region of the blots.
This material is thought to represent aggregates of
the overexpressed PS1 [29,30,42,44]. In addition to
the full-length and aggregated forms of PS1, we
also observed a speci¢c immunoreactive band at ap-
proximately 23 kDa, which may correspond to a PS1
carboxyl-terminal proteolytic fragment similar to
that described by others [41,43,45]. Con¢rmation of
the identity of the immunoreactive proteins was ob-
tained by adding excess peptide corresponding to
amino acids 333^397 of PS1 during the incubation
with the primary antibody. Under these conditions,
the bands at 66^95, 42 and 23 kDa were not de-
tected, whereas the apparent cross-reacting protein
band at 53 kDa remained (data not shown). The
expression levels of all of the electrophoretic forms
of PS1 were comparable in the cells expressing either
the wild-type or mutant PS1 constructs, consistent
with a report indicating that most FAD point muta-
tions do not a¡ect proteolytic processing of PS1 [46].
3.2. E¡ects of PS1 mutants on ERCGolgi tra⁄cking
of SWAPP751 in 293 cells
Like the LDL receptor, the Alzheimer’s L-amyloid
precursor protein (APP) undergoes a shift in electro-
phoretic mobility after it is O-glycosylated and sul-
Fig. 2. E¡ects of wild-type or mutant PS1 on post-translational
maturation of SWAPP751 in 293 cells. (A) Parallel cultures of
human HEK293 cells were co-transfected with expression vec-
tors encoding SWAPP751 combined with empty vector (none)
or vector encoding either PS1(wt), PS1(M146L), or PS1(L286V)
as indicated. Twenty four hours after transfection the medium
was changed and cells were pulse-labeled with [35S]methionine
for 10 min, then subjected to a 45 min chase as described in
Section 2. Cells were harvested immediately after pulse-labeling
(0 min) or after the chase (45 min) as indicated, and the immu-
noprecipitated APP was subjected to SDS-PAGE and £uorogra-
phy. The immature (i) and mature (m) forms of APP are indi-
cated by the arrows at the left of the ¢gure. (B) Immunoblot
analyses were performed on aliquots of the cell lysates from the
cultures harvested at the end of the chase period to determine
the steady-state levels of immature and mature intracellular
SWAPP751, using a monoclonal antibody that recognizes all
forms of APP. (C) Immunoblot analyses were performed on ali-
quots of the cell lysates from the cultures harvested at the end
of the chase period to con¢rm expression of the presenilin con-
structs as described in Section 2. Speci¢c bands corresponding
to overexpressed PS1 are indicated on the left of the ¢gure.
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fated in the medial-late Golgi compartment [47,48].
In a previous study, we determined that when
ERCGolgi transport is blocked in 293 cells, either
by treatment with brefeldin A or by overexpression
of a dominant-negative Rab1B mutant, the post-
translational maturation of APP is severely impaired
[33]. Therefore, to further evaluate the possible rela-
tionship between mutations in PS1 and ERCGolgi
protein transport, we coexpressed PS(wt),
PS1(M146L) or PS1(L286V) with the Swedish var-
iant of APP (SWAPP751) and examined the post-
translational processing of metabolically labeled
APP by pulse-chase analysis on the day after trans-
fection (Fig. 2A). As in the studies of the LDL re-
ceptor, the results of this experiment did not reveal
any obvious inhibitory e¡ects of the PS1 mutants on
the conversion of the immature ER form of
SWAPP751 (approximately 108 kDa) to the mature
form (approximately 135 kDa). In agreement with
these ¢ndings, the steady-state amounts of mature
versus immature SWAPP751 detected by immunoblot
analysis were not noticeably di¡erent in cells express-
ing wild-type or mutant PS1 compared to cells ex-
pressing no exogenous PS1 (Fig. 2B). Finally, as in
the previous experiments with the LDL receptor, ex-
pression of PS1 was con¢rmed in all of the cultures
transfected with PS1 vectors by the appearance of
immunodetectable bands corresponding to full-
length (42 kDa), aggregated (66^95 kDa), and pro-
teolytically cleaved (23 kDa) forms of PS1 in the
transfected cell cultures (Fig. 2C).
3.3. E¡ects of PS1 mutants on secreted products
derived from SWAPP751 in 293 cells
Cleavage of APP by K-secretase is thought to oc-
cur in a late compartment of the constitutive secre-
tory pathway [49^52]. Studies of the Swedish variant
of APP have suggested that the alternative L-secre-
tase cleavage occurs in an earlier Golgi compartment
[38,53,54]. In both cases the resulting soluble amino-
terminal exodomain fragments (s-APPK or s-APPL)
are subsequently secreted into the extracellular me-
Table 1
E¡ects of wild-type or mutant PS1 on the production of amyloid L-peptides in 293 cell cultures expressing the Swedish variant of
APP751
PS1 construct AL42 (pg/culture) ALTotal (pg/culture) AL42 (% of total AL) % Increase in AL42
None 64 þ 10 2970 þ 399 2.15 þ 0.04
wt 69 þ 6 3371 þ 312 2.05 þ 0.01 35
M146L 119 þ 5 3798 þ 110 3.13 þ 0.02 46
L286V 77 þ 6 2741 þ 166 2.80 þ 0.06 30
The concentrations of total AL (predominantly AL40) or AL42 were determined in aliquots of conditioned culture medium from the ex-
periment described in Fig. 3 using an established ELISA (see Section 2). Each value is a mean þ S.E. of separate determinations per-
formed on three parallel cultures. No AL42 was detected in the medium from the control 293 cells that were not transfected with the
plasmid encoding SWAPP751751.
Fig. 3. E¡ects of wild-type or mutant PS1 on steady-state con-
centrations of soluble APP derivatives secreted into the culture
medium. Cells were co-transfected with expression vectors en-
coding SWAPP751 combined with empty vector (none) or vector
encoding either PS1(wt), PS1(M146L), or PS1(L286V) as indi-
cated. Cells and medium were collected 48 h after transfection.
Immunoblot assays were performed on aliquots of the culture
medium, using monoclonal antibody 8E5, which detects both s-
APPK and s-APPL (s-APPTotal) (solid bars) or polyclonal anti-
body SW192, which detects only s-APPL derived from the
Swedish variant of APP (cross-hatched bars). In each case, the
bound secondary [125I]IgG was quanti¢ed by densitometric
scanning of autoradiograms as described in Section 2. Each val-
ue for s-APP (in arbitrary densitometer units) was expressed as
a ratio to the total intracellular SWAPP751 (arbitrary units) de-
tected by immunoblot assay of the corresponding cell mono-
layer using the 8E5 monoclonal antibody. Each bar represents
the mean þ S.E. derived from separate determinations on three
parallel cultures.
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dium. To determine whether mutations in PS1 might
disrupt intracellular tra⁄cking of SWAPP at points
distal to the initial ERCGolgi step, we performed
immunoblot analyses of conditioned medium to
compare the relative concentrations of total s-APP
(K+L forms) or s-APPL released from 293 cells that
had been co-transfected with SWAPP751 and various
PS1 constructs. The results depicted in Fig. 3 indicate
that neither the wild-type nor the mutant PS1 con-
structs had any signi¢cant cumulative e¡ect on the
secretion of soluble forms of APP into the culture
medium, implying that the K and L secretase proc-
essing steps were unimpaired.
Finally, we wished to verify that under the condi-
tions employed in the foregoing studies, the mutant
forms of PS1 did indeed cause an increase in cellular
production of AL42 relative to AL40 as reported pre-
viously [20]. Thus, samples of conditioned medium
from cultures that were expressing SWAPP751 in the
presence or absence of PS1 were subjected to ELISAs
for total AL and AL42, and the ratio of AL42/ALTotal
was determined (Table 1). The results con¢rmed that
the relative amounts of AL42 produced by the cells
expressing PS1(M146L) or PS1(L286V) were sub-
stantially elevated compared to cells that were ex-
pressing PS1(wt) or no exogenous PS1.
4. Discussion
The results demonstrate that under conditions
where expression of mutant forms of PS1 in 293 cells
produce a signi¢cant elevation of AL42 deposition
into the culture medium, there are no major disrup-
tions of ERCGolgi tra⁄cking and secretory proc-
essing of APP or an unrelated intracellular glycopro-
tein, the LDL receptor. Previous studies have shown
that such disruptions are readily detected by the
pulse-chase assays employed in the present studies
[33,35]. In recent years there has been much progress
in de¢ning the molecular events underlying the pack-
aging of ER-derived cargo proteins into transport
vesicles and their subsequent export to the Golgi
stack (for recent reviews see [55,56]). Increasing evi-
dence suggests that this is a selective process, with
di¡erent proteins being sorted into budding vesicles
and transported at di¡erent rates. However, all nor-
mally folded nascent protein molecules of a particu-
lar type (for example, APP751) are expected to behave
as a homogeneous pool as they are concentrated in
vesicles and exported to the Golgi compartment.
Based on these considerations, we conclude that mu-
tations in PS1 do not cause increased AL42 formation
by impairing the normal £ow of APP out of the ER
into the constitutive secretory pathway.
It remains possible that AL42 is derived from a
small pool of APP that becomes misfolded or other-
wise modi¢ed in the ER so that it fails to enter the
constitutive ERCGolgi export pathway. This minor
pool of APP could be subject to alternative tra⁄ck-
ing within specialized subdomains of the ER [57] or
perhaps between the ER and components of the en-
dosomal/lysosomal system [58]. Perturbations in such
pathways, possibly mediated by presenilin mutants,
would not be detected by conventional pulse-chase
analysis of Golgi-dependent protein processing. In
addition, our studies do not rule out the possibility
that mutant forms of PS1 could increase the biogen-
esis of AL42 by altering the internalization of APP
from the cell surface or the tra⁄cking of APP
through the endocytic pathway [59,60]. However,
this possibility seems remote in light of multiple re-
ports documenting the localization of PS1 in ER/
Golgi membranes [26^30] and evidence that long
forms of AL are generated predominantly in the lat-
ter compartments [31,32]. A ¢nal caveat that must be
considered in the interpretation of any studies where
presenilin is overexpressed in transfected cells is that
the properties of the overexpressed protein may not
completely re£ect those of the endogenous protein.
Of particular note is the fact that much of the over-
expressed PS1 tends to accumulate in a full-length
form, whereas endogenous PS1 appears to be e⁄-
ciently processed into N-terminal and C-terminal
fragments by an unde¢ned proteolytic pathway
[41,43]. Moreover, there is some evidence that alter-
native pathways for proteolytic processing of PS1
may occur in di¡erentiated neurons [61,62], and
that the protein may be present at subcellular sites
beyond the ER in such cells [26,63].
If presenilins do not participate directly in the traf-
¢cking of APP, then other mechanisms must be in-
voked to explain the ability of mutant presenilins to
a¡ect AL42 production. In this regard, recent reports
have uncovered several intriguing leads for future
exploration. For example, the co-immunoprecipita-
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tion studies of Xia et al. [45] indicate that presenilins
can associate directly with immature forms of APP
that reside in the ER, raising the possibility that such
interactions might a¡ect the susceptibility of APP to
proteolytic processing by a speci¢c Q-secretase re-
sponsible for generating AL42, but not AL40 [7,8].
Alternatively, one may envision mechanisms whereby
mutant presenilins could alter AL production
through indirect e¡ects on other metabolic pathways.
For instance, Guo et al. [64] have shown that PC12
cells expressing PS1(L286V) are more sensitive to
apoptotic stimuli than cells expressing PS1(wt), and
that this e¡ect may be related to changes in intra-
cellular calcium homeostasis. Along an entirely dif-
ferent line, the recent demonstration of presenilins in
the nuclear membrane and centrosomes suggests a
role for these proteins in chromatin organization
and/or chromosome segregation, distinct from their
function in APP processing [65]. The latter view
would be consistent with the ¢nding that PS1-de¢-
cient mice exhibit major defects in neurogenesis and
development of the axial skeleton [66]. Insofar as the
present studies argue against a direct role for prese-
nilins in the constitutive exocytic vesicular transport
machinery, they should help to narrow the focus of
future studies aimed at de¢ning the biological func-
tions of these intriguing proteins.
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